BioCentury | Jan 26, 2012
Distillery Therapeutics

Indication: Ophthalmic disease

...pain, epilepsy and fibromyalgia. The corresponding author has cofounded Visum Therapeutics Inc. to commercialize the work (see Visum...
...4). SciBX 5(4); doi:10.1038/scibx.2012.108 Published online Jan. 26, 2012 Patent application filed; exclusively licensed to Visum...
BioCentury | Jan 26, 2012
Targets & Mechanisms

Visum sees the light

...and dry age-related macular degeneration by preventing the toxic buildup of visual cycle byproducts. 1 Visum Therapeutics Inc....
...idea is to temporarily lower levels of all- trans -retinal," said William Harte, CEO of Visum...
...said Krzysztof Palczewski, chair of the Department of Pharmacology at Case Western and CSO of Visum...
Items per page:
1 - 2 of 2
BioCentury | Jan 26, 2012
Distillery Therapeutics

Indication: Ophthalmic disease

...pain, epilepsy and fibromyalgia. The corresponding author has cofounded Visum Therapeutics Inc. to commercialize the work (see Visum...
...4). SciBX 5(4); doi:10.1038/scibx.2012.108 Published online Jan. 26, 2012 Patent application filed; exclusively licensed to Visum...
BioCentury | Jan 26, 2012
Targets & Mechanisms

Visum sees the light

...and dry age-related macular degeneration by preventing the toxic buildup of visual cycle byproducts. 1 Visum Therapeutics Inc....
...idea is to temporarily lower levels of all- trans -retinal," said William Harte, CEO of Visum...
...said Krzysztof Palczewski, chair of the Department of Pharmacology at Case Western and CSO of Visum...
Items per page:
1 - 2 of 2